case_images: PMC3664744_01
case_images: Fundus photographs, the right and left eye of the 28-year-old man with ESCS
case_images: 10633_2012_9371_Fig1_HTML.jpg
case_images: PMC3664744_01_10633_2012_9371_Fig1_HTML.jpg
case_images: Fig1
case_images: Clinical features of macular cysts were noticed in both eyes (Fig. 1).
case_images: Optical coherence tomography (OCT) images (above) and mfERG recordings (below) of the right eye of the 28-year-old man with ESCS before and after a 6-month treatment with topical dorzolamide in comparison with the age-matched healthy control
case_images: 10633_2012_9371_Fig2_HTML.jpg
case_images: PMC3664744_01_10633_2012_9371_Fig2_HTML.jpg
case_images: Fig2
case_images: Loss of the normal foveal depression was observed in the right eye (Fig. 2). The improvement of BCDVA in the right eye corresponded with foveal thickness reduction from 482 mum initially to 359 mum at the 1st and to 226 mum at the 2nd follow-up visit (Fig. 2).
case_images: Full-field ERG of the ESCS patient
case_images: 10633_2012_9371_Fig3_HTML.jpg
case_images: PMC3664744_01_10633_2012_9371_Fig3_HTML.jpg
case_images: Fig3
case_images: It showed the absence of rod response, reduced and delayed waveforms in response to white flash (0 dB), both in scotopic and photopic conditions, reduced and delayed flicker recording (Fig. 3).
case_images: Right eye foveal thickness (FT) and visual acuity (VA) (above); implicit time (ms) and P1-wave response density (nV/deg2) of mfERG results (below) of ESCS patient, treated with dorzolamide during 6 consecutive visits
case_images: 10633_2012_9371_Fig4_HTML.jpg
case_images: PMC3664744_01_10633_2012_9371_Fig4_HTML.jpg
case_images: Fig4
case_images: BCDVA increased gradually during the treatment from 0.26 to 0.22 logMAR at the 1st, to 0.14 logMAR at the 2nd and to 0.1 logMAR at the 3rd follow-up examination (Fig. 4). P1 wave implicit time during first 2 months of treatment shortened, but then it returned to the value before the treatment (Fig. 4).  